4//SEC Filing
Oliva Adele C 4
Accession 0001192482-19-000420
CIK 0001561921other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 8:48 PM ET
Size
18.0 KB
Accession
0001192482-19-000420
Insider Transaction Report
Form 4
TELA Bio, Inc.TELA
Oliva Adele C
Director10% Owner
Transactions
- Purchase
Common Stock
2019-11-08$13.00/sh+153,846$1,999,998→ 888,664 total(indirect: By Quaker Bioventures II, L.P.) - Conversion
Common Stock
2019-11-13+345,489→ 1,234,153 total(indirect: By Quaker Bioventures II, L.P.) - Conversion
Common Stock
2019-11-13+516,947→ 1,751,100 total(indirect: By Quaker Bioventures II, L.P.) - Conversion
Series A Preferred Stock
2019-11-13−8,530,145→ 0 total(indirect: By Quaker Bioventures II, L.P.)→ Common Stock (345,489 underlying) - Conversion
Series B Preferred Stock
2019-11-13−12,763,434→ 0 total(indirect: By Quaker Bioventures II, L.P.)→ Common Stock (516,947 underlying) - Conversion
Warrant (right to buy)
2019-11-13−446,813→ 0 total(indirect: By Quaker Bioventures II, L.P.)Exercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (446,813 underlying) - Conversion
Warrant (right to buy)
2019-11-13+446,813→ 446,813 total(indirect: By Quaker Bioventures II, L.P.)Exercise: $28.65From: 2019-11-13Exp: 2027-01-18→ Common Stock (18,096 underlying)
Footnotes (6)
- [F1]Reflects 705,530 shares of common stock received as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F2]The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise.
- [F3]Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F4]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F5]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
- [F6]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
Documents
Issuer
TELA Bio, Inc.
CIK 0001561921
Entity typeother
Related Parties
1- filerCIK 0001339379
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 8:48 PM ET
- Size
- 18.0 KB